IgG antibodies in patients with pemphigus vulgaris before and after diagnosing with immunofluorescence.
Pemphigus is defined as a group of chronic self-immune vesicular diseases histologically recognized by inter-epidermic vesicles resulting from acantholysis. The aim of this study was to evaluate the precipitant and circulative IgG antibodies in patients with pemphigus vulgaris before and after treating with immunofluorescence. Sixty-two patients (34 females and 28 males) with clinically and pathologically confirmed P.V. were studied prospectively over a one year period of time during which direct and indirect immunofluorescent tests were performed before and after treatment. They had mild or moderate forms of disease. All patients received prednisolon 1-2 mg/kg/day and Azathioprine 2-3 mg/kg/day or methylpredisolon (1 g day(-1) for 4 days) and cyclophosphamide (500 mg/first day) pulse therapy due to general condition. Thirty- four females and 28 males enrolled, the mean age were 39.5 years (SD = 12.7). Before treatment, 10 and 52 cases were positive for skin depositing + or ++) and circulatory IgG (1/20 -1/60), respectively. Two to 3 month later, 37 were IgG positive with titers 1/20 to 1/160. The correlation between circulatory IgG before and after treatment was weakly positive (p = 0.05, r = 0.415). In the present study, treatment methods used for patients suffering from pemphigus vulgaris were not successful in significantly decreasing the circulative autoantibodies levels.
Depratment of Dermatology, Tabriz University of Medical Sciences, Tabriz, Iran.
Hamideh
H
Azimi
Depratment of Imunology, Tabriz University of Medical Sciences, Tabriz, Iran.
Jafar
J
Majidi
Depratment of Pathology, Tabriz University of Medical Sciences, Tabriz, Iran.
Rasul
R
Estakhri
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohamad
M
Goldust
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012867:Skin / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D001323:Autoantibodies; D015415:Biomarkers; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents